RECOMBINANT MODIFIED SMALLPOX VIRUS, ITS USAGE (VERSIONS) AND CELL LINE INFECTED BY VIRUS (VERSIONS) Russian patent published in 2003 - IPC

FIELD: biotechnology, immunobiotechnology. SUBSTANCE: invention relates to the development of recombinant modified smallpox virus Ankara (MVA) that is able to replicate in human cells. Virus MVA is used for preparing vaccine that is designated for animals and humans immunization. Cell lines infected with vector MVA-hTYP and MVA-LAInef, respectively, produce recombinant human tyrosinase, viral particles MVA-hTYP, recombinant protein Nef and viral particles MVA-LAInef. The prepared recombinant virus MVA is effective and absolutely safety expression vector that provides safety of vaccines and production of polypeptides. EFFECT: improved method of preparing, valuable medicinal properties. 23 cl, 9 dwg